Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
BMC Infectious Diseases|September 11, 2013
STI in remote communities: improved and enhanced primary health care (STRIVE) study protocol: a cluster randomised controlled trial comparing 'usual practice' STI care to enhanced care in remote primary health care services in AustraliaJames Ward, Skye McGregor, Rebecca J Guy, et al.
The Lancet Regional Health. Western Pacific|July 2, 2024
Clinical effectiveness and analytical quality of a national point-of-care testing network for sexually transmitted infections integrated into rural and remote primary care clinics in Australia, 2016-2022: an observational program evaluationLouise M Causer, James Ward, Kirsty Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2013
Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian womenJennifer Walker, Christopher K Fairley, Catriona S Bradshaw, et al.
BMJ Open|April 16, 2024
Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocolKate L Seib, Basil Donovan, Caroline Thng, et al.
The Medical Journal of Australia|February 28, 2023
Infectious syphilis in women and heterosexual men in major Australian cities: sentinel surveillance data, 2011-2019Allison Carter, Hamish McManus, James S Ward, et al.
American Journal of Epidemiology|February 3, 2021
A New Method for Estimating the Incidence of Infectious DiseasesHamish McManus, Denton Callander, Jason Asselin, et al.
The Lancet. HIV|April 17, 2023
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort studyDenton Callander, Hamish McManus, Richard T Gray, et al.
The Lancet. HIV|November 6, 2016
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE studyMark A Boyd, Janaki Amin, Patrick W G Mallon, et al.
The Lancet. Global Health|October 15, 2019
Strategies to improve control of sexually transmissible infections in remote Australian Aboriginal communities: a stepped-wedge, cluster-randomised trialJames Ward, Rebecca J Guy, Alice R Rumbold, et al.
Harm Reduction Journal|October 20, 2023
Evaluating a complex health promotion program to reduce hepatitis C among Aboriginal and Torres Strait Islander peoples in New South Wales, Australia: the Deadly Liver MobCarla Treloar, Kim Beadman, Mitch Beadman, et al.
Pageof 36